Loading...
•
Sep 30
AptarGroup Q3 2025 Earnings Report
Aptar delivered solid third quarter results with increased net income, higher earnings per share, and growth in closures and pharma segments.
Key Takeaways
Aptar posted strong Q3 2025 results with a 6% sales increase to $961 million and net income rising to $128 million. EPS grew to $1.92, and adjusted EPS reached $1.62. The pharma segment led with 18% growth in injectables. Adjusted EBITDA margin improved to 23.2%.
Net income increased 28% to $128 million compared to prior year
Reported EPS rose to $1.92; adjusted EPS was $1.62
Revenue increased 6% to $961 million, led by strong performance in Pharma and Closures
Adjusted EBITDA margin improved to 23.2% from 22.9% last year
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Revenue by Segment
Aptar Pharma Revenue
CapyFin.comAptar Beauty Revenue
CapyFin.comAptar Closures Revenue
CapyFin.com Forward Guidance
Aptar expects strong Pharma pipeline contributions and continued injectables growth in Q4, but anticipates a decline in emergency-use delivery system revenue in 2026.
Positive Outlook
- Pharma pipeline expected to contribute 7–10% of revenue annually
- Strong momentum in injectables, especially GLP-1 and biologics
- All three segments expected to contribute positively in Q4
- Operational discipline driving efficiency
- Diversified portfolio supports long-term growth
Challenges Ahead
- 2026 emergency-use systems revenue expected to decline from 2025
- Tough comparisons due to naloxone ramp-up in 2025
- Less favorable sales mix anticipated in Q4
- Customer inventory adjustments may impact future demand
- Macroeconomic uncertainties could affect segment performance